Skip to main content
. Author manuscript; available in PMC: 2013 Apr 18.
Published in final edited form as: Oncogene. 2011 Dec 5;31(42):4559–4566. doi: 10.1038/onc.2011.539

Figure 2. The KRAS-variant is associated with suboptimal debulking after neoadjuvant chemotherapy.

Figure 2

Surgical debulking after neoadjuvant chemotherapy is compared in ovarian cancer patients (n=116) with the KRAS-variant (n=26) or without (n=90). By chi-squared analysis the KRAS-variant patients are significantly more likely to be suboptimally debulked with greater residual disease (RD) than non-variant patients (p=0.044).